Alpha-synuclein levels in patients with multiple system atrophy: a meta-analysis

References

• Jaros E, Burn DJ. The pathogenesis of multiple system atrophy: past, present, and future. Mov Disord. 2000;15(5):784–788.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Neuropathology and pathophysiology of multiple system atrophy. Neuropathol Appl Neurobiol. 2012;38:379–380.
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372:249–263.
   PubMed Web of Science ®Google Scholar
• Gilman S, Wenning GK, Low PA, et al. Second consensus conference on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–676.
   PubMed Web of Science ®Google Scholar
• Campbell BC, McLean CA, Culvenor JG, et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem. 2001;76(1):87–96.
   PubMed Web of Science ®Google Scholar
• Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–98.
   PubMed Web of Science ®Google Scholar
• Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. The Lancet. 1999;354(9192):1771–1775.
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976–1990. Neurology. 1997;49(5):1284–1288.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Jeon BS, Lee JY, et al. Survival of Korean patients with multiple system atrophy. Mov Disord. 2011;26:909–912.
   PubMed Web of Science ®Google Scholar
• Wenning GK, Geser F, Krismer F, et al. European multiple system atrophy study group. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12:264–274.
   PubMed Web of Science ®Google Scholar
• Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in North America: a prospective cohort study. Lancet Neurol. 2015;14:710–719.
   PubMed Web of Science ®Google Scholar
• O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131:1362–1372.
   PubMed Web of Science ®Google Scholar
• Figueroa JJ, Singer W, Parsaik A, et al. Multiple system atrophy: prognostic indicators of survival. Mov Disord. 2014;29:1151–1157.
   PubMed Web of Science ®Google Scholar
• Petrovic IN, Ling H, Asi Y, et al. Multiple system atrophy–Parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 2012;27:1186–1190.
   PubMed Web of Science ®Google Scholar
• Calandra-Buonaura G, Guaraldi P, Sambati L, et al. Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue? Neurol Sci. 2013;34:1875–1878.
   PubMed Web of Science ®Google Scholar
• Fellner L, Jellinger KA, Wenning GK, et al. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol. 2011;121(6):675–693.
   PubMed Web of Science ®Google Scholar
• Prusiner SB, Woerman AL, Mordes DA, et al. Evidence for α-synuclein prions causing multiple system atrophy in humans with Parkinsonism. Proc Natl Acad Sci USA. 2015;112(38):E5308–E5317.
   PubMed Web of Science ®Google Scholar
• Arima K, Ueada K, Sunohara N, et al. NACP/a-synuclein immunoreactivity in ®brillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. (Berlin) 1998;96:439–444.
   PubMed Web of Science ®Google Scholar
• Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble a-synuclein.Ann Neurol. 1998;44:415–422.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Mori F, Kon T, et al. Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy. Acta Neuropathol Commun. 2015;3:29. DOI:10.1186/s40478-015-0208-0.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Mori F, Kon T, et al. Accumulation of phosphorylated α-synuclein in subpial and periventricular astrocytes in multiple system atrophy of long duration. Neuropathology. 2016;36(2):157–167.
   PubMed Web of Science ®Google Scholar
• Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14(2):467–475.
   PubMed Web of Science ®Google Scholar
• Kahle PJ, Haass C, Kretzschmar HA, et al. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J Neurochem. 2002;82:449–457.
   PubMed Web of Science ®Google Scholar
• Reynolds NP, Soragni A, Rabe M, et al. Mechanism of membrane interaction and disruption by alpha-synuclein. J Am Chem Soc. 2002;133:19366–19375.
   Google Scholar
• Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA. 2013;110:19555–19560.
   PubMed Web of Science ®Google Scholar
• Asi YT, Simpson JE, Heath PR, et al. Alphasynuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62:964–970.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim C, Lee SJ. Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev. 2010;3:283–287.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Willey-Blackwell; 2008.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
   PubMed Web of Science ®Google Scholar
• Aerts MB, Esselink RA, Abdo WF, et al. CSF alpha-synuclein does not differentiate between Parkinsonian disorders. Neurobiol Aging. 2012;33(2):430e1e3.
   Web of Science ®Google Scholar
• Foulds PG, Yokota O, Thurston A, et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and dementia with Lewy bodies. Neurobiol Dis. 2012;45(1):188–195.
   PubMed Web of Science ®Google Scholar
• Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol. 2012;69(11):1445e52.
   Google Scholar
• Lee PH, Lee G, Park HJ, et al. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm. 2006;113(10):1435–1439.
   PubMed Web of Science ®Google Scholar
• Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical Parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–1247.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230e40.
   Web of Science ®Google Scholar
• Mondello S, Constantinescu R, Zetterberg H, et al. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord. 2014;20(4):382–387.
   PubMed Web of Science ®Google Scholar
• Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570–580.
   PubMed Web of Science ®Google Scholar
• Sun ZF, Xiang XS, Chen Z, et al. Increase of the plasma α-synuclein levels in patients with multiple system atrophy. Mov Disord. 2014;29(3):375–379.
   PubMed Web of Science ®Google Scholar
• Tateno F, Sakakibara R, Kawai Takayuki, et al. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson's disease, dementia with Lewy body, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord. 2012;2(3):213e6.
   Google Scholar
• Tong J, Wong H, Guttman M, et al. Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation Brain. 2009;133(1):172–188.
   PubMedGoogle Scholar
• Bisaglia M, Schievano E, Caporale A, et al. The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: a cooperative role. Biopolymers. 2006;84:310–316.
   PubMed Web of Science ®Google Scholar
• Abdo WF, Bloem BR, Van Geel WJ, et al. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging. 2007;28(5):742–747.
   PubMed Web of Science ®Google Scholar
• Hu X, Yang Y, Gong D. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis. Neurol Sci. 2017;38(3):407–414.
   PubMed Web of Science ®Google Scholar
• Nelson PT, Schmitt FA, Jicha GA, et al. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol. 2010;257(11):1875–1881.
   PubMed Web of Science ®Google Scholar
• Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78(8):905–906.
   PubMed Web of Science ®Google Scholar
• Caranci G, Piscopo P, Rivabene R, et al. Gender differences in Parkinson's disease: focus on plasma α-synuclein. J Neural Transm. 2013;120(8):1209–1215.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, El-Agnaf OM, Marcus K, et al. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers Med. 2010;4:683–699.
   PubMed Web of Science ®Google Scholar
• Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133:713–726.
   PubMed Web of Science ®Google Scholar
• Hirohata M, Ono K, Morinaga A, et al. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation. Neuroscience Lett. 2011;491(1):48–52.
   PubMed Web of Science ®Google Scholar